EGFR and non-small cell lung carcinoma: Osimertinib (Tagrisso) is a second-line TKI that has demonstrated selectivity for T790M-resistant mutation in patients with advanced NSCLC and disease progression after prior EGFR-TKI therapy (Figure 1).